Protocol for Outcome Evaluation of Ayahuasca-Assisted Addiction Treatment: The Case of Takiwasi Center
This paper presents the Ayahuasca Treatment Outcome Project (ATOP) protocol for evaluating an ayahuasca-assisted, integrative addiction rehabilitation programme at the Takiwasi Center, using mixed quantitative and qualitative methods to assess outcomes and therapeutic mechanisms. It emphasises the role of treatment setting and outlines core principles, measures, strengths and limitations to guide future research on long-term residential psychedelic-assisted treatments.
Authors
- Anja Loizaga-Velder
Published
Abstract
The present study describes the protocol for the Ayahuasca Treatment Outcome Project (ATOP) with a special focus on the evaluation of addiction treatment services provided through Takiwasi Center, the first ATOP study site. The goal of the project is to assess treatment outcomes and understand the therapeutic mechanisms of an Ayahuasca-assisted, integrative treatment model for addiction rehabilitation in the Peruvian Amazon. The proposed intervention protocol highlights the significance of treatment setting in the design, delivery, and efficacy of an addiction rehabilitation program that involves the potent psychedelic tea known as Ayahuasca. After describing the context of the study, we put forth details about our mixed-methods approach to data collection and analysis, with which we seek to gain an understanding of why, how, and for whom this specific ayahuasca-assisted treatment program is effective across a range of outcomes. The ATOP protocol employs qualitative research methods as a means to determine which aspects of the setting are meaningful to clients and practitioners, and how this may correlate with outcome measures. This paper delineates the core principles, methods, and measures of the overall ATOP umbrella, then discusses the role of ATOP in the context of the literature on long-term residential programs. To conclude, we discuss the strengths and limitations of the protocol and the intended future of the project.
Research Summary of 'Protocol for Outcome Evaluation of Ayahuasca-Assisted Addiction Treatment: The Case of Takiwasi Center'
Introduction
Rush and colleagues frame their work within a resurgence of interest in psychedelic and traditional medicines as potential treatments for substance use and other mental disorders, driven by limitations in mainstream addiction medicine and gaps in global mental health coverage. The introduction summarises historical, cultural and clinical interest in ayahuasca — a two-plant Amazonian brew containing DMT and harmala alkaloids — and notes observational and qualitative evidence suggesting reductions in problematic substance use, alongside plausible neuropharmacological and psychological mechanisms. The authors emphasise the importance of non-pharmacological factors, commonly referred to as set (individual mindset, intentions and preparation) and setting (social, ritual and therapeutic context), which may interact with neurobiology to shape outcomes. The paper describes the Ayahuasca Treatment Outcome Project (ATOP) and presents the study protocol for its first site, the Takiwasi Center in Peru. The stated aim is to evaluate treatment outcomes and explore therapeutic mechanisms of an ayahuasca-assisted, integrative residential model for addiction rehabilitation using a mixed-methods, longitudinal cohort design with extended follow-up. The authors position ATOP as a multisite umbrella with common core measures and methods, and present Takiwasi as a naturalistic case-study setting in which to investigate how elements of set and setting relate to a range of recovery-oriented outcomes.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Author
- APA Citation
Rush, B., Marcus, O., García, S., Loizaga-Velder, A., Loewinger, G., Spitalier, A., & Mendive, F. (2021). Protocol for Outcome Evaluation of Ayahuasca-Assisted Addiction Treatment: The Case of Takiwasi Center. Frontiers in Pharmacology, 12. https://doi.org/10.3389/fphar.2021.659644
References (58)
Papers cited by this study that are also in Blossom
Galvão-Coelho, N. L., de Almeida, R. N., de Menezes Galvão, A. C. et al. · Frontiers in Psychology (2019)
Araújo, A. M., Carvalho, F. M., Carvalho, M. et al. · Archives of Toxicology (2015)
Argento, E., Capler, R., Thomas, G. et al. · Drug and Alcohol Review (2019)
Barbosa, P., Mizumoto, S., Bogenschutz, M. P. et al. · Drug Testing and Analysis (2012)
Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)
Bogenschutz, M. P., Johnson, M. W. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2016)
Bogenschutz, M. P., Pommy, J. A. · Drug Testing and Analysis (2012)
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)
Bouso, J. C., González, D., Fondevila, S. et al. · PLOS ONE (2012)
Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)
Show all 58 referencesShow fewer
Carhart-Harris, R. L., Nutt, D. J. · Journal of Psychopharmacology (2017)
Carhart-Harris, R. L., Bolstridge, &. M., Day, C. M. J. et al. · Psychopharmacology (2017)
Carhart-Harris, R. L., Erritzoe, D., Haijen, E. C. H. M. et al. · Psychopharmacology (2017)
Carhart-Harris, R. L., Roseman, L., Haijen, E. C. H. M. et al. · Journal of Psychopharmacology (2018)
Domínguez-Clavé, E., Soler, J., Elices, M. et al. · Brain Research Bulletin (2016)
Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · Therapeutic Advances in Psychopharmacology (2016)
Dupuis, D. · Salud Colectiva (2018)
Dupuis, D. · Transcultural Psychiatry (2021)
Fábregas, J. M., González, D., Fondevila, S. et al. · Drug and Alcohol Dependence (2010)
Franquesa, A., Sainz-Cort, A., Gandy, S. et al. · Psychiatry Research (2018)
Galvão-Coelho, N. L., de Menezes Galvão, A. C., de Almeida, R. N. et al. · Journal of Psychopharmacology (2020)
Galvão-Coelho, N. L., Marx, W., Sinclair, J. et al. · Psychopharmacology (2021)
Garcia-Romeu, A., Griffiths, R. R., Johnson, M. W. · Current Drug Abuse Reviews (2015)
Garcia-Romeu, A., Davis, A. K., Fire Erowid et al. · Journal of Psychopharmacology (2019)
González, D., Carvalho, M., Aixalá, M. et al. · OMEGA - Journal of Death and Dying (2017)
Griffiths, R. R., Johnson, M. W. · Journal of Psychopharmacology (2016)
Griffiths, R. R., Hurwitz, E. S., Davis, A. K. et al. · PLOS ONE (2019)
Halpern, J. H., Sherwood, A. R., Passie, T. et al. · Medical Science Monitor (2008)
Hartogsohn, I. · Journal of Psychopharmacology (2016)
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)
Johnson, M. W., Garcia-Romeu, A., Johnson, P. S. et al. · Journal of Psychopharmacology (2017)
Johnson, M. W., Hendricks, P. S., Barrett, F. S. et al. · Pharmacology and Therapeutics (2019)
Kjellgren, A., Eriksson, A., Norlander, T. · Journal of Psychoactive Drugs (2009)
Kometer, M., Schmidt, A., Bachmann, R. et al. · Biological Psychiatry (2012)
Kraehenmann, R., Preller, K. H., Scheidegger, M. et al. · Biological Psychiatry (2015)
Krebs, T. S., Johansen, P. Ø. · Journal of Psychopharmacology (2012)
Lafrance, A., Loizaga-Velder, A., Fletcher, J. et al. · Journal of Psychoactive Drugs (2017)
Liester, M. B., Prickett, J. I. · Journal of Psychoactive Drugs (2012)
Loizaga-Velder, A., Verres, R. · Journal of Psychoactive Drugs (2014)
Majic, T., Schmidt, T. T., Gallinat, J. · Journal of Clinical Psychopharmacology (2015)
Morales-García, J. A., de la Fuente Revenga, M., Alonso-Gil, S. et al. · Scientific Reports (2017)
Kraehenmann, R., Nielson, E. M., May, D. G. et al. · Frontiers in Pharmacology (2018)
Nunes, A. A., Dos Santos, R. G., Osório, F. L. et al. · Journal of Psychoactive Drugs (2016)
Osório, F. L., Sanches, R. F., Macedo, L. et al. · brazilian Journal of Psychiatry (2015)
Palhano-Fontes, F., Andrade, K. C., Tófoli, L.F. et al. · PLOS ONE (2015)
Palhano-Fontes, F., Barreto, D., Onias, H. et al. · Psychological Medicine (2018)
Pasquini, L., Palhano-Fontes, F., Araújo, D. B. · Journal of Psychopharmacology (2020)
Riba, J., Urbano, G., Morte, A. et al. · Psychopharmacology (2001)
Rothberg, R. L., Azhari, N., Haug, N. A. et al. · Journal of Psychopharmacology (2020)
Sanches, R. F., Osório, F. L., Dos Santos, R. G. et al. · Journal of Clinical Psychopharmacology (2016)
Strassman, R. J., Qualls, C. R., Uhlenhuth, E. H. et al. · JAMA Psychiatry (1994)
Talin, P., Sanabria, E. · International Journal of Drug Policy (2017)
Thomas, G., Lucas, P., Rielle Capler, N. et al. · Current Drug Abuse Reviews (2013)
Timmermann, C., Roseman, L., Williams, L. et al. · Frontiers in Psychology (2018)
Tófoli, L. F., De Araujo, D. B. · International Review of Neurobiology (2016)
Tupper, K. W., Wood, E., Yensen, R. et al. · Canadian Medical Association Journal (2015)
Uthaug, M. V., Mason, N. L., Toennes, S. W. et al. · Psychopharmacology (2021)
Vollenweider, F. X., Kometer, M. · Nature Reviews Neuroscience (2010)
Cited By (2)
Papers in Blossom that reference this study
Perkins, D., Ruffell, S. G. D., day, K. et al. · Frontiers in Neuroscience (2023)
O'shaughnessy, D. M., Sarnyai, Z., Quirk, F. et al. · SSM Qualitative Research in Health (2022)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.